Table 2:
Response and Survival
| Overall Response Rate (ORR) |
Complete Response Rate (CR) |
Progression-free Survival (PFS) [2-year (95% CI)] |
Overall Survival (OS) [2-year (95% CI)] |
|
|---|---|---|---|---|
| All DLBCL | 54% (26/48) | 38% (18/48) | 34% (21-47%) | 36% (23-49%) |
| Disease histology | ||||
| Non-GCB DLBCL, NOS | 62% (8/13) | 62% (8/13) | 39% (14-63%) | 39% (14-63%) |
| HGBCL-DH-BCL6 | 33% (1/3) | 33% (1/3) | 33% (1-77%) | 33% (1-77%) |
| THRLBCL | 60% (3/5) | 20% (1/5) | 40% (5-75%) | 40% (5-75%) |
| GCB DLBCL, NOS | 33% (4/12) | 0% (0/12) | 8% (1-31%) | 17% (3-41%) |
| HGBCL-DH-BCL2 | 67% (10/15) | 53% (8/15) | 47% (23-68%) | 47% (23-68%) |
| Line of therapy | ||||
| Second-line therapy | 80% (12/15) | 73% (11/15) | 60% (32-80%) | 60% (32-80%) |
| Third or later-line therapy | 42% (14/33) | 21% (7/33) | 23% (11-38%) | 25% (13-41%) |
| Transformed lymphoma | 47% (7/15) | 33% (5/15) | 29% (11-51%) | 28% (10-51%) |
| Prior CAR-T | 45% (9/20) | 20% (4/20) | 30% (12-50%) | 30% (12-50%) |
| Refractory per SCHOLAR-1 | 44% (12/27) | 19% (5/27) | 21% (8-37%) | 24% (11-41%) |
Abbreviations: DLBCL, diffuse large B-cell lymphoma; Non-GCB DLBCL, NOS, non-germinal center B-cell diffuse large B-cell lymphoma, not otherwise specified; HGBCL-DH-BCL6, high-grade B-cell lymphoma, double-hit, with MYC and BCL6 rearrangements; THRLBCL, T-cell/histiocyte-rich large B-cell lymphoma; GCB DLBCL, NOS, germinal center B-cell diffuse large B-cell lymphoma, not otherwise specified; HGBCL-DH-BCL2, high-grade B-cell lymphoma, double-hit, with MYC and BCL2 rearrangements; CAR-T, chimeric antigen receptor T-cell therapy.